Last reviewed · How we verify
Pregabalin-Lyrica
Pregabalin-Lyrica, marketed by Rush University Medical Center, is a well-established drug with a key composition patent expiring in 2028. Its primary strength lies in its strong market presence and established therapeutic use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Pregabalin-Lyrica |
|---|---|
| Also known as | Lyrica. |
| Sponsor | Rush University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver (PHASE4)
- Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain (PHASE4)
- Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients (NA)
- Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial (NA)
- The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With Fibromyalgia (NA)
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregabalin-Lyrica CI brief — competitive landscape report
- Pregabalin-Lyrica updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI